1476727-50-0

1476727-50-0 structure

Name: TAK-915
Chemical Name: N-{(1S)-1-[3-Fluoro-4-(trifluoromethoxy)phenyl]-2-methoxyethyl}-7-methoxy-2-oxo-2,3-dihydropyrido[2,3-b]pyrazine-4(1H)-carboxamide
CAS Number: 1476727-50-0
Molecular Formula: C₁₉H₁₈F₄N₄O₅
Molecular Weight: 458.364
Catalog: Signaling Pathways Metabolic Enzyme/Protease Phosphodiesterase (PDE)
Create Date: 2020-01-20 15:54:56
Modify Date: 2025-08-21 11:25:14
TAK-915 (TAK915) is a highly potent, selective, brain-penetrating and orally active phosphodiesterase 2A (PDE2A) inhibitor with IC50 of 0.61 nM; dispalys 4100-fold selectivity over PDE1A, and >20,000-fold over other PDE isoforms; robustly increased cGMP levels in the rat brain, attenuates MK-801-induced episodic memory deficits in rats. Schizophrenia Phase 1 Clinical

Name	N-{(1S)-1-[3-Fluoro-4-(trifluoromethoxy)phenyl]-2-methoxyethyl}-7-methoxy-2-oxo-2,3-dihydropyrido[2,3-b]pyrazine-4(1H)-carboxamide
Synonyms	Pyrido[2,3-b]pyrazine-4(1H)-carboxamide, N-[(1S)-1-[3-fluoro-4-(trifluoromethoxy)phenyl]-2-methoxyethyl]-2,3-dihydro-7-methoxy-2-oxo- N-{(1S)-1-[3-Fluoro-4-(trifluoromethoxy)phenyl]-2-methoxyethyl}-7-methoxy-2-oxo-2,3-dihydropyrido[2,3-b]pyrazine-4(1H)-carboxamide

Description	TAK-915 (TAK915) is a highly potent, selective, brain-penetrating and orally active phosphodiesterase 2A (PDE2A) inhibitor with IC50 of 0.61 nM; dispalys 4100-fold selectivity over PDE1A, and >20,000-fold over other PDE isoforms; robustly increased cGMP levels in the rat brain, attenuates MK-801-induced episodic memory deficits in rats. Schizophrenia Phase 1 Clinical
References	References 1. Mikami S, et al. J Med Chem. 2017 Sep 28;60(18):7677-7702. View Related Products by Target Phosphodiesterase (PDE) Schizophrenia